Literature DB >> 31819710

Role of real-world evidence in informing cancer care: lessons from colorectal cancer.

A Batra1,2, W Y Cheung1,2.   

Abstract

The term "real-world evidence" (rwe) describes the analysis of data that are collected beyond the context of clinical trials. The use and application of rwe have become increasingly common and relevant, especially in oncology, because there is growing recognition that randomized controlled trials (rcts) might not be sufficiently representative of the entire patient population that is affected by cancer, and that specific clinical research questions might be best addressed by real-world data. In this brief review, our main aim is to highlight the role of rwe in informing cancer care, particularly focusing on specific examples from colorectal cancer. Our hope is to illustrate the ways in which rwe can complement rcts in improving the understanding of cancer management and how rwe can facilitate cancer treatment decisions for real-world patients encountered in routine clinical care. 2019 Multimed Inc.

Entities:  

Keywords:  Real-world evidence; colorectal cancer

Mesh:

Year:  2019        PMID: 31819710      PMCID: PMC6878934          DOI: 10.3747/co.26.5625

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  26 in total

1.  Generalisability of Common Oncology Clinical Trial Eligibility Criteria in the Real World.

Authors:  S Karim; Y Xu; S Kong; O Abdel-Rahman; M L Quan; W Y Cheung
Journal:  Clin Oncol (R Coll Radiol)       Date:  2019-05-25       Impact factor: 4.126

2.  The use of chemotherapy in older patients with stage II and III colon cancer: Variation by age and era of diagnosis.

Authors:  Susan L Green; David E Dawe; Zoann Nugent; Winson Y Cheung; Piotr M Czaykowski
Journal:  J Geriatr Oncol       Date:  2018-08-10       Impact factor: 3.599

Review 3.  Older cancer patients in cancer clinical trials are underrepresented. Systematic literature review of almost 5000 meta- and pooled analyses of phase III randomized trials of survival from breast, prostate and lung cancer.

Authors:  Cita Dunn; Andrew Wilson; Freddy Sitas
Journal:  Cancer Epidemiol       Date:  2017-11-07       Impact factor: 2.984

4.  When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?

Authors:  Jessica M Franklin; Sebastian Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2017-09-25       Impact factor: 6.875

5.  Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials.

Authors:  Narjust Duma; Sejal M Kothadia; Tariq U Azam; Siddhartha Yadav; Jonas Paludo; Jesus Vera Aguilera; Miguel Gonzalez Velez; Thorvardur Ragnar Halfdanarson; Julian R Molina; Joleen M Hubbard; Ronald S Go; Aaron S Mansfield; Alex A Adjei
Journal:  Oncologist       Date:  2018-11-09

6.  Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials.

Authors:  D G Haller; M J O'Connell; T H Cartwright; C J Twelves; E F McKenna; W Sun; M W Saif; S Lee; G Yothers; H-J Schmoll
Journal:  Ann Oncol       Date:  2015-01-16       Impact factor: 32.976

7.  Time to adjuvant chemotherapy and survival outcomes among patients with stage 2 to 3 rectal cancer treated with preoperative chemoradiation.

Authors:  Gillian Gresham; Winson Y Cheung; Caroline Speers; Ryan Woods; Hagen Kennecke
Journal:  Clin Colorectal Cancer       Date:  2014-11-20       Impact factor: 4.481

8.  Patterns of practice with third-line anti-EGFR antibody for metastatic colorectal cancer.

Authors:  M Y Ho; D J Renouf; W Y Cheung; H J Lim; C H Speers; C Zhou; H F Kennecke
Journal:  Curr Oncol       Date:  2016-10-25       Impact factor: 3.677

9.  Effect of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.

Authors:  Renata D'Alpino Peixoto; Aalok Kumar; Caroline Speers; Daniel Renouf; Hagen F Kennecke; Howard J Lim; Winson Y Cheung; Barbara Melosky; Sharlene Gill
Journal:  Clin Colorectal Cancer       Date:  2014-11-04       Impact factor: 4.481

10.  Capecitabine as adjuvant treatment for stage III colon cancer.

Authors:  Chris Twelves; Alfred Wong; Marek P Nowacki; Markus Abt; Howard Burris; Alfredo Carrato; Jim Cassidy; Andrés Cervantes; Jan Fagerberg; Vassilis Georgoulias; Fares Husseini; Duncan Jodrell; Piotr Koralewski; Hendrik Kröning; Jean Maroun; Norbert Marschner; Joseph McKendrick; Marek Pawlicki; Riccardo Rosso; Johannes Schüller; Jean-François Seitz; Borut Stabuc; Jerzy Tujakowski; Guy Van Hazel; Jerzy Zaluski; Werner Scheithauer
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

View more
  6 in total

1.  Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen.

Authors:  Nieves Martínez-Lago; Soledad Cameselle García; Beatriz Alonso de Castro; Martín I Gómez-Randulfe Rodríguez; Marta Carmona Campos; Paula González Villarroel; Mercedes Salgado Fernández; Juan C De la Cámara Gómez; Carlos Romero Reinoso; Antía Cousillas Castiñeiras; José Carlos Méndez Méndez; Yolanda Vidal Insua; Ana Fernández-Montes
Journal:  PLoS One       Date:  2022-06-03       Impact factor: 3.752

2.  Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019.

Authors:  Sini Marika Eskola; Hubertus Gerardus Maria Leufkens; Andrew Bate; Marie Louise De Bruin; Helga Gardarsdottir
Journal:  Clin Pharmacol Ther       Date:  2021-11-16       Impact factor: 6.903

3.  Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective.

Authors:  Laurent Azoulay
Journal:  Oncologist       Date:  2022-09-02       Impact factor: 5.837

4.  Eligibility of real-world patients with metastatic breast cancer for clinical trials.

Authors:  Atul Batra; Shiying Kong; Winson Y Cheung
Journal:  Breast       Date:  2020-10-17       Impact factor: 4.380

5.  Harnessing real-world evidence to reduce the burden of noncommunicable disease: health information technology and innovation to generate insights.

Authors:  Kelly H Zou; Jim Z Li; Lobna A Salem; Joseph Imperato; Jon Edwards; Amrit Ray
Journal:  Health Serv Outcomes Res Methodol       Date:  2020-11-06

6.  Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.

Authors:  Adam Brufsky; Xianchen Liu; Benjamin Li; Lynn McRoy; Rachel M Layman
Journal:  Target Oncol       Date:  2021-08-02       Impact factor: 4.493

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.